Galectin Therapeutics Inc. (GALT)

4.30
0.08 1.83
NASDAQ
Prev Close 4.38
Open 4.44
Day Low/High 4.23 / 4.47
52 Wk Low/High 3.10 / 9.49
Volume 293.54K
Exchange NASDAQ
Shares Outstanding 45.55B
Market Cap 197.69M
Div & Yield N.A. (N.A)

Latest News

First Week Of January 2021 Options Trading For Galectin Therapeutics (GALT)

First Week Of January 2021 Options Trading For Galectin Therapeutics (GALT)

Investors in Galectin Therapeutics Inc saw new options begin trading this week, for the January 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week Of GALT September 21st Options Trading

First Week Of GALT September 21st Options Trading

Investors in Galectin Therapeutics Inc saw new options begin trading this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GALT options chain for the new September 21st contracts and identified one put and one call contract of particular interest.

Company Profile For Galectin Therapeutics Inc.

Company Profile For Galectin Therapeutics Inc.

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer.

GALT Crosses Above Average Analyst Target

GALT Crosses Above Average Analyst Target

In recent trading, shares of Galectin Therapeutics Inc have crossed above the average analyst 12-month target price of $8.33, changing hands for $8.75/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Galectin Therapeutics To Present Late-Breaker Oral Presentation At The International Liver Congress 2018

Galectin Therapeutics To Present Late-Breaker Oral Presentation At The International Liver Congress 2018

GR-MD-02 treatment in NASH cirrhosis patients without esophageal varices shows statistically significant and clinically meaningful effects

Galectin Therapeutics Granted Patents In China And Japan That Support NASH And Cancer Immunotherapy Clinical Development Programs

Galectin Therapeutics Granted Patents In China And Japan That Support NASH And Cancer Immunotherapy Clinical Development Programs

The broad protection of these patents opens doors to partnerships in the world's second- and third-largest pharmaceutical markets

Insiders Seeing Green With GALT At New 52-Week High

Insiders Seeing Green With GALT At New 52-Week High

In trading on Tuesday, shares of Galectin Therapeutics Inc touched a new 52-week high of $6.74/share. That's a 617.02% rise, or $5.8 per share from the 52-week low of $0.94 set back on 01/23/2017.

Galectin Therapeutics To Present Results From Phase 2b NASH-CX Trial On December 5, 2017

Galectin Therapeutics To Present Results From Phase 2b NASH-CX Trial On December 5, 2017

Company to Host Investor Conference Call at 8:30 A.M. ET

Galectin Therapeutics To Present Clinical Data At The Liver Meeting® 2017 Demonstrating The Ability Of Non-Invasive Test To Identify Clinically Significant Portal Hypertension In Patients With Compensated NASH Cirrhosis

Galectin Therapeutics To Present Clinical Data At The Liver Meeting® 2017 Demonstrating The Ability Of Non-Invasive Test To Identify Clinically Significant Portal Hypertension In Patients With Compensated NASH Cirrhosis

Research to be presented demonstrates VCTE liver stiffness measurement is a surrogate for identifying portal hypertension in patients with compensated NASH cirrhosis